Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records

Diabetes, Obesity and Metabolism

Volumn 20, Issue 4, 2018, Pages 974-984

  Patorno, Elisabetta ^a   Gopalakrishnan, Chandrasekar ^a   Franklin, Jessica M ^a   Brodovicz, Kimberly G ^b   Masso Gonzalez, Elvira ^c   Bartels, Dorothee B ^c,d   Liu, Jun ^a   Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

administrative data; electronic medical records; glucose lowering medications; linkage; type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CLAIMS BASED STUDY; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ELECTRONIC MEDICAL RECORD; FACTUAL DATABASE; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT IDENTIFICATION; PATIENT INFORMATION; PROPENSITY SCORE; RESEARCH SUBJECT; RISK FACTOR; STUDY DESIGN; UNITED STATES; ADMINISTRATIVE CLAIMS (HEALTH CARE); BLOOD; CLINICAL TRIAL (TOPIC); DRUG EFFECT; ELECTRONIC HEALTH RECORD; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ADMINISTRATIVE CLAIMS, HEALTHCARE; ADULT; AGED; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LINAGLIPTIN; MALE; MIDDLE AGED; UNITED STATES;

EID: 85040640331     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13184     Document Type: Article

References (30)

1. Prevention CfDCa. National diabetes statistics report. 2014; http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed May 3, 2016.
2. World Health Organization. Diabetes Fact Sheet. 2016. http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed May 3, 2016.
3. FDA. Guidance for Industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2008; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed May 3, 2016.
4. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326.
5. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335.
6. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247-2257.
7. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-242.
8. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
9. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
10. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323-337.
11. Schneeweiss S, Seeger JD, Jackson JW, Smith SR. Methods for comparative effectiveness research/patient-centered outcomes research: from efficacy to effectiveness. J Clin Epidemiol. 2013;66(8 Suppl):S1-S4.
12. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19(8):858-868.
13. Schneeweiss S. Improving therapeutic effectiveness and safety through big healthcare data. Clin Pharmacol Ther. 2016;99(3):262-265.
14. Patorno E, Patrick AR, Garry EM, et al. Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia. 2014;57(11):2237-2250.
15. Patorno E, Garry EM, Patrick AR, et al. Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review. Drug Saf. 2015;38(3):295-310.
16. Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98(3):253-259.
17. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-522.
18. Hansen L. The Truven Health MarketScan Databases for Life Sciences Researchers. 2017; https://truvenhealth.com/Portals/0/Assets/2017-MarketScan-Databases-Life-Sciences-Researchers-WP.pdf. Accessed August 22, 2017.
19. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127(8 pt 2):757-763.
20. Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(suppl 2):69-80.
21. Patorno EGC, Zorina OI, Schneeweiss S, Bartels DB, Liu J, Seeger JD. Dynamic channeling among initiators of a recently marketed medication for type 2 diabetes mellitus (T2DM). Pharmacoepidemiol Drug Saf. 2015;24:565-566.
22. Huse DM. Linking Insurance Claims and Medical Records for Outcome Research. White paper. 2012. dan.huse@truvenhealth.com.
23. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141(12):929-937.
24. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.
25. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15(5):291-303.
26. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075-1079; discussion 1081–1090.
27. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther. 2007;82(2):143-156.
28. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
29. Eng PM, Seeger JD, Loughlin J, Clifford CR, Mentor S, Walker AM. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. Pharmacoepidemiol Drug Saf. 2008;17(3):297-305.
30. FDA. Guidance for Industry - diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention 2008. https://www.fda.gov/downloads/Drugs/../Guidances/ucm071624.pdf. Accessed August 9, 2017.